Regardless of weak Q1, developers reiterate strong pre-sales momentum in FY24
The company's digital interventions and data-led decision making on product assortments, pricing and promotions also helped to boost sales
Brokerages expect 3-4% hit to earnings per share for FY25
Caustic Reaction: Sector expected to underperform as brokerages slash profit estimates
Lower depreciation led to a 45 per cent increase in adjusted net profit and the same was 25-35 per cent higher than what the street had estimated
Sector is expected to underperform as brokerages cut profit estimates
The company maintained its pre-sales guidance of Rs 12,000 crore to Rs 13,000 crore, riding on 11.2 million square feet of launches
Recent rally, soft outlook for O2C business may pull stock down
Analysts see investors to be out on the tiles
Orders remained robust while Q1 margins came in line with estimates
Muted sequential Q1 performance may cap near-term upsides
ON THE MENU: While Westlife remains an outlier, valuations for most players on the higher side
United Spirits is expected to post an overall 11 per cent decline in revenues in Q1 FY24
The positive from TCS' point of view, which reported flat sales growth QoQ, was the strong order book which topped the $10.2-billion mark
But valuations rich after the run-up in the last three months
Street remains cautious about the sector due to lower price realisations and fears about El Nino's impact on the monsoon
Sharp rally and integration/execution challenges may cap upsides for the stock
Pharma players with a major exposure to US mkt such as Sun Pharma, Lupin, Zydus Life, Dr Reddy's, Aurobindo, Torrent have been outperformers hitting their 52-week highs over the last couple of weeks
The stock has gained 56 per cent over three months on consecutive quarters of high bookings
The stock is trading at 16 times its estimated FY25 consolidated earnings per share